Skip to main content

Table 2 Effect ovarian cancer ascites OVC346 and OVC509 on TRAIL IC50 in primary samples of ovarian cancer cells

From: The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer

Primary samples ascites OVC346 ascites OVC509
ascites - + - +
218A 7.2 ± 1.3 12 ± 1.1 7 ± 0.7 14.5 ± 0.8
231A 4.8 ± 0.7 5.5 ± 0.7 4.4 ± 0.8 7.5 ± 0.6
238A 16 ± 1.8 19.5 ± 0.9 15 ± 0.4 > 30
285A 12 ± 2.1 18.8 ± 1.4 14 ± 1.1 > 30
318A 5.5 ± 0.5 7.5 ± 0.7 5.7 ± 0.6 12 ± 0.9
327A 5.3 ± 0.7 7.5 ± 0.5 5.2 ± 0.7 9.7 ± 0.8
339A 7.8 ± 1.1 14.5 ± 0.7 7.5 ± 1.2 19.5 ± 0.6
341T 10.8 ± 1.3 16.5 ± 1.2 10 ± 0.4 19.5 ± 0.9
346A 6.5 ± 0.9 9.2 ± 0.6 6.5 ± 0.6 16 ± 1